WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 561233
CAS#: 28822-58-4
Description: IBMX is a competitive nonselective phosphodiesterase inhibitor. IBMX raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity. IBMX is also a nonselective adenosine receptor antagonist.
MedKoo Cat#: 561233
Name: IBMX
CAS#: 28822-58-4
Chemical Formula: C10H14N4O2
Exact Mass: 222.1117
Molecular Weight: 222.25
Elemental Analysis: C, 54.04; H, 6.35; N, 25.21; O, 14.40
Synonym: IBMX
IUPAC/Chemical Name: 3-Isobutyl-1-methylxanthine
InChi Key: APIXJSLKIYYUKG-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
SMILES Code: O=C(N1C)N(CC(C)C)C2=C(NC=N2)C1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 222.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Yoshimura K, Tada H, Anzai C. [Cystic fibrosis]. Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):606-11. Review. Japanese. PubMed PMID: 9645146.
2: Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002 Jul-Aug;56(6):453-9. Review. PubMed PMID: 12166544.
3: Manganiello VC, Smith CJ, Newman AH, Rice K, Degerman E, Belfrage P. Hormonal regulation of adipocyte particulate "low Km" cAMP phosphodiesterase. J Cyclic Nucleotide Protein Phosphor Res. 1986-1987;11(7):497-511. Review. PubMed PMID: 2450112.
4: Ashcroft SJ, Sugden MC, Williams IH. Carbohydrate metabolism and the glucoreceptor mechanism. Horm Metab Res Suppl. 1980;Suppl 10:1-7. Review. PubMed PMID: 6161068.
5: Bruns RF, Katims JJ, Annau Z, Snyder SH, Daly JW. Adenosine receptor interactions and anxiolytics. Neuropharmacology. 1983 Dec;22(12B):1523-9. Review. PubMed PMID: 6199685.
6: Howell SL, Tyhurst M. Insulin secretion: the effector system. Experientia. 1984 Oct 15;40(10):1098-105. Review. PubMed PMID: 6208051.
7: O'Shea Alvarez MS. 3T3 cells in adipocytic conversion. Arch Invest Med (Mex). 1991 Apr-Jun;22(2):235-44. Review. PubMed PMID: 1726451.
8: Muravyov A, Tikhomirova I. Role Ca(2+) in mechanisms of the red blood cells microrheological changes. Adv Exp Med Biol. 2012;740:1017-38. doi: 10.1007/978-94-007-2888-2_47. Review. PubMed PMID: 22453982.
9: Fredholm BB. Gastrointestinal and metabolic effects of methylxanthines. Prog Clin Biol Res. 1984;158:331-54. Review. PubMed PMID: 6084844.
10: Weir GC, Leahy JL, Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev. 1986;2(1-2):125-61. Review. PubMed PMID: 2424696.
11: Zufall F. Cyclic AMP-gated cation channels of olfactory receptor neurons. EXS. 1993;66:135-45. Review. PubMed PMID: 7505646.
12: Rosen OM, Smith CJ, Hirsch A, Lai E, Rubin CS. Recent studies of the 3T3-L1 adipocyte-like cell line. Recent Prog Horm Res. 1979;35:477-99. Review. PubMed PMID: 92801.
13: Niemeyer G. Retinal pharmacology in the perfused cat eye. Doc Ophthalmol. 1988 Mar-Apr;68(3-4):327-35. Review. PubMed PMID: 2456907.
14: Gilbard JP. The tear film: pharmacological approaches and effects. Adv Exp Med Biol. 1994;350:377-84. Review. PubMed PMID: 7518184.
15: Arimura A, Culler MD, Matsumoto K, Kanda M, Itoh Z, Murphy W, Shively JE, Palkovits M. Growth hormone releasing factors in the brain and the gut: chemistry, actions, and localization. Peptides. 1984;5 Suppl 1:41-4. Review. PubMed PMID: 6207512.
16: Hill HZ, Li W, Xin P, Mitchell DL. Melanin: a two edged sword? Pigment Cell Res. 1997 Jun;10(3):158-61. Review. PubMed PMID: 9266603.
17: Pekala PH, Moss J. 3T3-L1 preadipocyte differentiation and poly(ADP-ribose) synthetase. Mol Cell Biochem. 1983;53-54(1-2):221-32. Review. PubMed PMID: 6194420.
18: Tsai LC, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol. 2011 Dec;11(6):670-5. doi: 10.1016/j.coph.2011.09.003. Epub 2011 Sep 29. Review. PubMed PMID: 21962440; PubMed Central PMCID: PMC4034742.
19: Newby AC, Assender JW, Evans MA, Lim K, Bennett MR, Evan GI. Transduction pathways for growth stimulatory and inhibitory actions of vasoactive agents. Exp Nephrol. 1994 Mar-Apr;2(2):94-100. Review. PubMed PMID: 7521776.
20: Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J. Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann N Y Acad Sci. 1993 May 31;680:290-301. Review. PubMed PMID: 7685575.
